An observational study in Pneumonia Ventilator Associated, sponsored by Centre Hospitalier Sud Francilien. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-09.
Sponsored by Centre Hospitalier Sud Francilien · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies in Pneumonia, Ventilator-Associated with a site in France — 20 open to participants now, 22 under way, 3 of them phase 3. Pneumonia, Ventilator-Associated · France.
Among the 80 studies in Pneumonia, Ventilator-Associated with a site in France, this one is the 21st largest by planned enrollment of the 33 observational ones that give a count, is one of 5 that started in 2025, is one of 33 observational ones, reaches primary completion later than 7 of the 21 other live ones, and was the 74th registered.
420 studies on the registry are indexed under Pneumonia, Ventilator-Associated; 83 are open to participants now.
Browse Pneumonia, Ventilator-Associated studies →20 of the 80 studies in Pneumonia, Ventilator-Associated with a site in France are open now. Recruiting first, the newest first:
Region Skane · Sites in France, Portugal, Sweden
Ages 18+
Centre Hospitalier Universitaire de Nīmes · Sites in France
Ages 18+
University Hospital, Limoges · Sites in France
Ages 18+
Nantes University Hospital · Sites in France, Guadeloupe
Ages 18+
CHU de Reims · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 47 Pneumonia, Ventilator-Associated studies recruiting now, 36 (77%) set no upper age limit and 6 (13%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 17 · Phase 4 2
First in 2003; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 170 across 132 observational studies indexed under Pneumonia, Ventilator-Associated.
Median enrollment 161 across the 47 interventional studies, 268 across the 33 observational. Of the 49 that completed or were terminated, 7 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 80 have an industry lead sponsor. The 10 most frequent:
Centre Hospitalier Sud Francilien is the lead sponsor of 58 studies on the registry; 13 are open to participants now.
Centre Hospitalier Sud Francilien has 2 studies filed under Pneumonia, Ventilator-Associated — fewer than ten, so there is no comparison to draw.
7 of the studies in Pneumonia, Ventilator-Associated with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05843786Phase 3Hospices Civils de LyonHuman Recombinant Interferon Gamma in the Treatment of Ventilator-acquired Pneumonia in ICU Patients | 2027-07-30 |
| NCT06607055Centre Hospitalier Intercommunal Aix-PertuisImmunity Markers in Intensive Care Patients and Ventilator-associated Pneumonia | 2026-12 |
| NCT05719259European Clinical Research Alliance for Infectious Diseases (ECRAID)Perpetual Observational Study - Ventilator Associated Pneumonia | 2026-12-01 |
| NCT06653933University Hospital, GrenobleStudy of Sleep Quality in the Intensive Care Unit and Association with Weaning from Invasive Ventilation in Patients with Chronic Obstructive Bronchopneumopathy. | 2027-02-01 |
| NCT05915663Centre Hospitalier le MansImpact of the Choice of Gastric Tube Placement Sites on the Incidence of Ventilator Associated Pneumonia | 2027-04-07 |
Add all 7 to your calendar (.ics) → With an account.
Among the 80 studies in Pneumonia, Ventilator-Associated with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to to analyze respiratory samples performed in mechanically ventilated ICU patients and to assess whether the SRLF criteria for defining VAP were respected among patients admited to the Intensive care medicine at a regional hospital en France
Ventilator-associated pneumonia (VAP) is a lung infection that occurs after more than 48 hours of mechanical ventilation. It is of particular interest because it affects between 5-40% of ICU patients depending on the study and diagnostic criteria, with a relatively low attributable mortality (around 10%), but with increased morbidity, notably in terms of the duration of mechanical ventilation and ICU length of stay. In addition, it is the leading cause of nosocomial infection in the ICU, accounting for up to 25% of antibiotic use for hospital-acquired infections.
The diagnosis of VAP is based on clinico-radiological criteria: the appearance or worsening of a radiological pulmonary infiltrate, an inflammatory syndrome, the appearance of secretions, increased oxygen dependency and/or worsening of shock, confirmed by a positive respiratory sample.
The diagnostic challenge lies in the fact that the signs and symptoms are not pathognomonic of VAP and may be common to other conditions. On the other hand, patients may be colonized by pathogens without actually having VAP.
For this reason, scientific societies propose criteria to better target patients for whom a respiratory sample should be taken and antibiotic therapy initiated.
In 2017, the French Society of Intensive Care Medicine (SRLF) and the French Society of Anaesthesia and Intensive Care (SFAR) published recommendations on ICU-associated pneumonia, with some minor variations compared with the 2005 ATS/IDSA criteria.
Our study aims to analyze respiratory samples performed in mechanically ventilated ICU patients and to assess whether the SRLF criteria for defining VAP were respected.
Population includes all patients admitted to the intensive care unit for the selected period, under mechanical ventilation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Adult patients (\>18 years) under mechanical ventilation for \>48 hours and with a positive respiratory sample
Other: Diagnostic tedst
* Radiologic signs: 2 consecutive thorax x-ray with new onset pneumonia AND * One of the following criteria * Fever \>38,3°C without any other cause * Leucocytes \< 4000/mm3 or ≥ 12000 /mm3 * AND at least two of the following * Purulent secretions * Cough or dyspnoea * Desaturation or increase in FiO2 (+20%)
SRLF VAP criteria
Describe whether the respiratory samples obtained from ICU patients after \>48 hours of mechanical ventilation for suspected VAP met, or did not meet, the 2017 SRLF diagnostic criteria
Time frame: at day 0
microbial ecology in the ICU of CHSF
Prevalence of MDR in the respiratory samples
Time frame: at day 0
antibiotic consumption generated by VAP
To evaluate antibiotic consuming related to VAP episodes to the total antibiotic consuming in the Intensive care unit
Time frame: at day 0
morbidity and mortality associated with VAP
Mortality and mechanical ventilation duration among patients diagnosed of VAP
Time frame: at day 0
duration of antibiotic therapy for a VAP episode
Duration of antibiotherapy among patients with VAP
Time frame: at day 0
characteristics of the initial antibiotic therapy
Number and class of antibiotics of the initial antibiotic therapy
Time frame: at day 0
Evaluate the adequacy of the initial antibiotic therapy
Adequation of the initial therapy compared to the definitive therapy: maintain, increase or reduce the spectrum or number of antibiotics
Time frame: at day 0
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Jun 2026, 10 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pneumonia, Ventilator-Associated →
Centre Hospitalier Sud Francilien